is a physiologically relevant agonist released by various sources, including activated platelets, with complex effects mediated via activation of P2 purinergic receptors. ATP-induced endothelial cell (EC) production of prostacyclin and nitric oxide is recognized, and EC barrier enhancement evoked by ATP has been described. ATP effects on EC barrier function and vascular permeability, however, remain poorly characterized. Although the mechanisms involved are unclear, we previously identified activation of the small GTPase Rac and translocation of cortactin, an actin-binding protein, as key to EC barrier augmentation induced by simvastatin and sphingosine 1-phosphate and therefore examined the role of these molecules in ATP-induced EC barrier enhancement. ATP induced rapid, dose-dependent barrier enhancement in human pulmonary artery EC as measured by transendothelial electrical resistance, with a peak effect appreciable at 25 min (39% increase, 10 M) and persisting at 2 h. These effects were associated with rearrangement of the EC actin cytoskeleton, early myosin light chain phosphorylation, and spatially defined (cell periphery) translocation of both Rac and cortactin. ATP (10 M)-treated EC demonstrated a significant increase in Rac activation relative to controls, with a maximal effect (ϳ4-fold increase) at 10 min. Finally, ATP-induced barrier enhancement was markedly attenuated by reductions of either Rac or cortactin (small interfering RNA) relative to controls. Our results suggest for the first time that ATP-mediated barrier protection is associated with cytoskeletal activation and is dependent on both Rac activation and cortactin. vascular permeability; cytoskeleton; actin EXTRACELLULAR NUCLEOTIDES, including ATP, are known to mediate a number of physiologically relevant vascular functions via effects on both smooth muscle cells and endothelial cells (EC). The effects of ATP on the endothelium are of particular interest as large amounts of these nucleotides are released by activated platelets (as well as EC) in response to shear stress and in the setting of acute inflammation (2, 3, 19, 34) . Accordingly, local effects of ATP on the endothelium may be relevant to a variety of clinical settings characterized by derangements in endothelial function and the increased vascular permeability observed in inflammatory lung syndromes such as acute lung injury (ALI), a condition with significant morbidity and mortality and for which there are currently few treatment options. Although it is known that ATP-induced increases in EC intracellular Ca 2ϩ with the subsequent release of nitric oxide and prostacyclin promote vasodilation (5, 15, 23), the direct effects of ATP on EC with respect to activation of the actin cytoskeleton and barrier function remain poorly characterized. ATP affects intracellular EC signaling events through activation of specific P 2 purinergic receptors (20). This family of receptors is divided into two groups, ion-coupled P2X receptors, composed of seven cloned subtypes, and G proteincoupled P2Y receptors, composed of six subtypes. Of these, P2X 4 , P2X 5 , P2Y 11 , P2Y 1 , and P2Y 2 are the most highly expressed subtypes in EC (28, 31) . Whereas the activation of P2X receptors promotes the influx of extracellular Ca 2ϩ , binding of adenosine nucleotides to P2Y receptors leads to increased inositol 1,4,5-trisphosphate (IP 3 ) via G protein-mediated phospholipase C (PLC) activation culminating in the release of Ca 2ϩ from intracellular stores (1). Our lab has characterized (7, 8) several agonists that also induce IP 3 -mediated increases in cytosolic calcium, including thrombin, a serine protease, and the phospholipid sphingosine 1-phosphate (S1P), which is also released by activated platelets. Notably, although both of these agonists are potent activators of the EC actin cytoskeleton, they exert diametrically opposite effects on EC barrier function as thrombin induces rapid and pronounced barrier disruption and S1P is a robust EC barrier enhancer (7, 8) . Both thrombin and S1P induce EC myosin light chain (MLC) phosphorylation and actomyosin contraction via the coordinate activities of the Ca 2ϩ /calmodulin-dependent MLC kinase (MLCK) and Rho kinase (6, 7, 8) . However, beyond these effects there are several discernible differences. For example, unlike thrombin, S1P activates the small GTPase Rac in association with translocation of the 80-/85-kDa actin-binding protein cortactin to the cell periphery and augmentation of the cortical actin ring, events that may account for its barrier-enhancing properties (6, 13). Hence, although ATP also induces IP 3 -mediated increases in cytosolic Ca 2ϩ , its effects with respect to EC cytoskeletal rearrangement and barrier function cannot be predicted on this basis alone. Accordingly, we sought to characterize and examine specific mechanisms underlying EC cytoskeletal activation and barrier enhancement by ATP.
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MATERIALS AND METHODS

Measurement of transendothelial electrical resistance.
Human pulmonary artery EC (HPAEC) were grown to confluence in complete medium over evaporated gold microelectrodes connected to a phasesensitive lock-in amplifier. Experiments relying on small interfering RNA (siRNA) transfection were performed in 1% serum medium as described below. Transendothelial electrical resistance (TER) was measured in response to agonists applied directly to the medium with an electrical cell-substrate impedance sensing system (ECIS) (Applied BioPhysics, Troy, NY) as previously described (9) . As cells adhere and spread out on the microelectrode TER increases, whereas cell retraction, rounding, or loss of adhesion is reflected by a decrease in TER. For each experiment TER values were plotted at 5-min intervals and were derived from the average values measured over the surrounding 3-min period. Data points from each 5-min interval were then averaged across all experiments of a given condition and plotted.
MLC phosphorylation in intact endothelium. HPAEC were analyzed for MLC phosphorylation by SDS-PAGE followed by Western immunoblotting with antibody specific for diphosphorylated MLC as previously described (25) . Blots were scanned and quantitatively analyzed with ImageQuant software (version 5.2, Amersham Biosciences, Piscataway, NJ).
Immunofluorescent microscopy. Confluent HPAEC grown on coverslips were exposed to experimental conditions, fixed with 3.7% formaldehyde, and permeabilized with 0.25% Triton X-100. After blocking with 2% BSA, cells were exposed to primary antibodies for 60 min. Fluorescently tagged secondary antibodies were applied for 60 min in the dark. F-actin was detected by staining with Texas red-conjugated phalloidin. Cells were imaged with a Nikon videoimaging system.
Rac activation assay. Determination of Rac activation (Rac-GTP) was performed with a commercially available kit (Upstate, Lake Placid, NY). Rac-GTP was pulled down with a p21-activated kinase (PAK)1-glutathione S-transferase fusion protein, and samples were subjected to Western blotting and detection with anti-Rac1 antibody.
Silencing RNA. For construction of the siRNA, a transcriptionbased kit from Ambion (Austin, TX) was used (Silencer siRNA construction kit). The siRNA sequences targeting human cortactin and Rac1 were generated with mRNA sequences from GenBank (gi: 20357555, 29792301). Potential target sequences were aligned to the human genome database in a BLAST search to eliminate sequences with significant homology to other human genes. For each mRNA (or scramble), two targets were identified. Specifically, cortactin target sequence 1 (5Ј-AATGCCTGGAAATTCCTCATT-3Ј), cortactin target sequence 2 (5Ј-AAACAGAATTTCGTGAACAGC-3Ј), Rac1 target sequence 1 (5Ј-AAAACTTGCCTACTGATCAGT-3Ј), Rac1 target sequence 2 (5Ј-AACTTGCCTACTGATCAGTTA-3Ј), scramble sequence 1 (5Ј-AAGAGAAATCGAAACCGAAAA-3Ј) and scramble sequence 2 (5Ј-AAGAACCCAATTAAGCGCAAG-3Ј) were used. EC cells were then transfected with siRNA, using siPORTamine as transfection reagent. Cells (ϳ40% confluent) were serum starved for 2 h, followed by incubation with 3 M (1.5 M of each siRNA) target siRNA (or scramble siRNA or no siRNA) for 6 h in serum-free medium. Medium with serum was then added (1% serum final concentration) for 42 h before Western blotting or functional assays were conducted.
Statistical analysis. One-way ANOVA was used to compare the means of data from two or more different experimental groups. If a significant difference was present by ANOVA (P Ͻ 0.05), a least significant difference test was performed post hoc. Subsequently, differences between groups were considered statistically significant when P Ͻ 0.05. Results are expressed as means Ϯ SE. Fig. 1 . Effect of ATP on endothelial cell (EC) barrier function. Human pulmonary artery EC (HPAEC) were grown to confluence on gold microelectrodes before treatment with ATP and measurement of transendothelial electrical resistance (TER). Relative to vehicle controls, ATP (1-100 M) induced a rapid, dose-dependent increase in barrier function as measured by TER (n ϭ 3 for each group). A maximal effect was observed at 20 -30 min after ATP at all concentrations, whereas higher doses of ATP (10 or 100 M) were associated with persistent barrier enhancement (Ͼ2 h). 
RESULTS
EC barrier function is enhanced by ATP. TER was used as a sensitive measure of EC monolayer barrier integrity and barrier function. HPAEC grown to confluence in complete medium and then treated with 100 M ATP exhibited a rapid and significant increase in TER (45% increase at 25 min), indicative of enhanced barrier function, with a persistent effect after Ͼ2 h (Fig. 1) . A dose-dependent response was observed, as 1 and 10 M ATP affected a significant but lesser increase in TER (20% and 39% increase at peak effects, respectively). On the basis of these results, we chose to use 10 M ATP for subsequent experiments, as a significant difference between the maximal effects of 10 M and 100 M was not appreciable. Moreover, these concentrations of ATP are most consistent with concentrations used in other reports (10, 22) .
EC cytoskeletal rearrangement and cortactin translocation by ATP. Immunofluorescent images were obtained to link the effects of ATP on EC TER with cytoskeletal changes. EC monolayers treated with ATP (10 M) demonstrated dramatic cytoskeletal rearrangement characterized by decreased central actin stress fibers and enhanced cortical actin that was fully realized at 30 min (Fig. 2A) . These changes were associated with reductions in the number of paracellular gaps consistent with augmentation of barrier integrity. Additionally, evidence of the peripheral translocation of cortactin was noted at 5 min and was even more pronounced at 30 min, consistent with the time course of actin cytoskeletal rearrangement (Fig. 2B) .
ATP induces EC MLC phosphorylation. EC cytoskeletal rearrangement is driven by actomyosin contraction, which is dependent on the phosphorylation of MLC. We measured MLC diphosphorylation in HPAEC treated with ATP (10 M) by Western blotting, using an antibody specific for diphosphorylated MLC (Fig. 3A) . MLC phosphorylation levels were dramatically increased early (ϳ7-fold increase at 1 and 5 min), consistent with the observed time course of cytoskeletal rearrangement. Levels were decreased at 10 min and were back to Fig. 3 . EC myosin light chain (MLC) phosphorylation by ATP. Confluent HPAEC were treated with ATP (10 M) before Western blotting and probing with antibody specific for diphosphorylated MLC (MLC-pp). Relative to vehicle controls, ATP-induced a rapid and dramatic increase in MLC diphosphorylation that was significantly attenuated at 10 min (A; n ϭ 3, *P Ͻ 0.05 relative to vehicle). Separately, HPAEC monolayers treated with ATP (10 M) and then probed for diphosphorylated MLC (B) demonstrate a predominant localization at the periphery of EC (arrows) that is evident at 5 min and no longer appreciable at 20 min, consistent with the observed time course of actin cytoskeletal rearrangement. In contrast, thrombin (1 U/ml, 5 min), a barrier-disruptive agonist, induces increased MLC phosphorylation throughout EC that corresponds to transcellular actin stress fiber formation. baseline within 20 min. We next obtained immunofluorescent images to determine the site of ATP-induced MLC phosphorylation. Relative to vehicle, HPAEC grown to confluence and then treated with ATP (10 M) demonstrated increased MLC phosphorylation at the cell periphery, the site of cortical actin enhancement, at 5 min (Fig. 3B) . This increased MLC phosphorylation was no longer evident at 20 min, consistent with our Western blotting data and the observed time course of active cytoskeletal rearrangement. The peripheral distribution of MLC phosphorylation in response to ATP stands in stark contrast to the colocalization of MLC phosphorylation with actin stress fibers in response to thrombin, an agonist known to induce MLC phosphorylation in the setting of EC contraction and barrier disruption. Although quantitative differences corresponding to our Western blotting densitometry are not appreciable, these images clearly demonstrate qualitative differences in MLC phosphorylation that correspond to the barrier effects of thrombin and ATP.
ATP induces endothelial cell Rac activation. As we had previously identified EC barrier augmentation in association with enhanced cortical actin as associated with activation of the small GTPase Rac, we measured levels of Rac activation in EC challenged with ATP (10 M). Relative to vehicle, a significant increase in activated Rac was evident at 10 min (ϳ4-fold increase; Fig. 4A ). Moreover, Rac activation was increased as early as 1 min, although these results did not achieve significance.
Activation of the small GTPases is dependent of isoprenylation and ultimately translocation to the cell periphery, where they can bind to GTP. Immunofluorescent images of EC treated with ATP (10 M) followed by an antibody specific for Rac1 confirmed increased translocation of Rac to the cell periphery within 5 min (Fig. 4B) and no longer appreciable at 20 min. The time course of these events was similar to that of Rac activation measured by Western blotting.
ATP-induced EC barrier enhancement is dependent on both Rac activation and cortactin translocation.
To establish the functional significance of both Rac activation and cortactin translocation in ATP-induced EC barrier enhancement we used specific siRNAs designed to reduce either Rac or cortactin expression and then measured TER. EC were transfected with Rac siRNA, cortactin siRNA, or scramble siRNA and grown to confluence overlying ECIS gold microelectrodes. Separately, untransfected cells were used as a control. EC were then treated with ATP (10 M), and TER was measured. Notably, although Rac activity has been shown to be necessary for maintenance of EC monolayer integrity (32), there was no appreciable difference in baseline electrical resistances measured among untransfected EC and any of the siRNA-transfected EC. We speculate that this may be due to sufficient residual Rac activity in our Rac-silenced EC as well as differences attributable to the specific techniques used to measure barrier integrity. Although scramble siRNA attenuated ATPinduced barrier enhancement relative to untransfected controls, Rac silencing elicited a further and highly significant attenuation (60% reduction relative to scramble siRNA at peak effect of ATP; Fig. 5B ). In separate experiments, silencing of cortactin resulted in a significant reduction in peak ATP effects (47% reduction relative to scramble; Fig. 5C ). These data confirm an important functional role for both Rac and cortactin in ATPmediated EC barrier enhancement.
DISCUSSION
As ATP is a potentially prevalent constituent of the endothelial microenvironment under a variety of clinically relevant conditions, an understanding of its effect on the endothelium is of significant interest. The literature is highly inconsistent with respect to ATP-induced EC barrier regulation, with both barrier disruption, characterized by increased permeability, and barrier enhancement described (10, 29) . We now extend the initial report of ATP-induced EC barrier enhancement (10) and demonstrate for the first time the dynamic EC cytoskeletal rearrangement by ATP in association with specific biochemical events associated with cytoskeletal activation including rapid MLC phosphorylation, activation of the small GTPase Rac, and cortactin translocation. In addition, we have identified these latter two events as necessary to achieve maximal EC barrier enhancement by ATP.
Early EC MLC dephosphorylation by ATP has also been reported (10, 22) . Although our findings should not necessarily supersede the work of previous investigators, our data from several complementary experiments are notable as ATP-induced EC barrier enhancement, measured by TER, was associated with decreased paracellular gaps and enhanced cortical actin histologically, and dynamic actin cytoskeletal rearrangement in this setting was associated with increased MLC phosphorylation, a requirement for actomyosin contraction and cytoskeletal activation. Indeed, we have also described EC MLC dephosphorylation by ATP (14) ; however, these findings were evident only at time points (30 min) later than those of the present study and are compatible with rapid cytoskeletal rearrangement by ATP that is fully realized by 30 min. Finally, the barrier-enhancing effects of ATP were dependent on both activation of the small GTPase Rac and translocation of the actin-binding protein cortactin, events associated with EC barrier enhancement and consistent with the effects of other agonists and stimuli our lab has studied that also promote EC barrier function (6, 12) .
EC Rac activation by ATP is a novel finding; however, the mechanisms responsible for this event remain speculative. Consistent with the known effects of ATP, recent evidence suggests that Rac activation is dependent on intracellular Ca and activation of protein kinase C (PKC) (17, 26) . At the same time, however, there is evidence that ATP-induced EC barrier enhancement occurs independent of effects on Ca 2ϩ or PKC (21) . Unfortunately, the authors who reported these findings did not assess Rac activation but were able to abolish ATPinduced EC barrier enhancement by inhibition of PLC, an effector of IP 3 -mediated release of Ca 2ϩ from intracellular stores. Although the possibility exists that the rapid activation of Rac by ATP is mediated by events that are PLC dependent but Ca 2ϩ independent, this finding would be highly unexpected. Separately, specific effectors of Rac activation have now been identified including several guanine nucleotide exchange factors (GEFs) as well as the disruption of Rac from guanine dissociation inhibitor, which enables Rac activation via GEF-mediated GTP exchange (4, 18) . Further investigation of the potential role of these mediators in ATP-induced Rac activation is required.
We previously characterized EC cortactin translocation in association with Rac activation, and a linkage between these two events is supported by the colocalization of cortactin with Rac on EC stimulation at sites of polymerized actin peripherally as well as evidence of cortactin phosphorylation and translocation by PAKs, downstream effectors of Rac whose activation can be inhibited by the inhibition of Rac (6, 7, 12) . Our findings now are consistent with the growing body of evidence (30, 33) , implicating an important association of these two molecules with each other in the setting of EC barrier enhancement.
Ultimately, characterization of the EC barrier-enhancing properties of ATP may have profound clinical implications. Already, our lab has begun using a murine model of ALI to investigate the attenuation of inflammation via effects on lung vascular permeability by intravenously administered ATP. Furthermore, elucidation of the precise mechanisms involved in these effects, particularly as they are relevant to other barrierenhancing agonists that we have previously investigated as potentially novel treatment strategies in ALI (11, 16, 24) , may lead to highly specific and effective therapies for a variety of clinical conditions characterized by increased vascular permeability.
